Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer ; volume:19 ; number:1 ; day:24 ; month:6 ; year:2019 ; pages:1-2 ; date:12.2019
BMC cancer ; 19, Heft 1 (24.6.2019), 1-2, 12.2019

Creator: Perez, Edith A.
Haas, Sanne Lysbet de
Eiermann, Wolfgang
Barrios, Carlos H.
Toi, Masakazu
Im, Young-Hyuck
Conte, Pier Franco
Martin, Miguel
Pienkowski, Tadeusz
Pivot, Xavier B.
Burris, Howard A.
Stanzel, Sven
Patre, Monika
Ellis, Paul Anthony

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-019-5831-x

URN: urn:nbn:de:101:1-2019092423244342924791

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:36 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Perez, Edith A.
Haas, Sanne Lysbet de
Eiermann, Wolfgang
Barrios, Carlos H.
Toi, Masakazu
Im, Young-Hyuck
Conte, Pier Franco
Martin, Miguel
Pienkowski, Tadeusz
Pivot, Xavier B.
Burris, Howard A.
Stanzel, Sven
Patre, Monika
Ellis, Paul Anthony
SpringerLink (Online service)

Other Objects (12)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Hochschulschrift

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Hochschulschrift

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Hochschulschrift

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients

Related objects

Reset password